Volume 1, Number 4—October 1995
An Outbreak of Hemoytic Uremic Syndrome Associated with Antibiotic Treatment of Hospital Inpatients for Dysentery
|Antibiotic combination||Developed HUS(10)||Total (42)||HUS rate/100||Risk ratio a||confidence interval b|
|Ineffective c antibiotics without nalidixic acid d-j||6||12||50||4.3||1.3-15|
|Ampicillin combinations without nalidixic acid d-f||5||7||71||6.2||1.9-20|
|Ineffective antibiotics without nalidixic acid or ampicillin g-j||1||5||20||1.7||0.22-14|
|Ampicillin and nalidixic acid with (2) or without metronidazole (3)||1||3||33||2.9||0.40-20|
|Trimethoprim-sulfamethoxazole, nalidixic acid and metronidazole||0||1||0||0|
|Nalidixic acid with (24) or without (2) metronidazole (reference)||3||26||12||1.0||Reference|
a Relative to the reference antibiotic combination (nalidixic acid with or without metronidazole).
b Taylor series approximation standard.
c Antibiotics to which the outbreak strain of S. dysenteriae type 1 was resistant (ampicillin, trimethoprim-sulfamethoxazole) or which are ineffective against shigella (metronidazole, gentamicin, or erythromycin).
d Ampicillin and metronidazole (4 patients). e Ampicillin, metronidazole, and gentamicin (2 patients).
f Ampicillin only (1 patient). g Trimethoprim-sulfamethoxazole and metronidazole (1 patient).
h Trimethoprim-sulfamethoxazole, erythromycin, and metronidazole (1 patient). i Metronidazole only (2 patients).
j Erythromycin and metronidazole (1 patient).
- Page created: December 20, 2010
- Page last updated: December 20, 2010
- Page last reviewed: December 20, 2010
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)